Sorrento Therapeutics, Inc.

SRNE

US83587F2020

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:59:59 2024-04-24 pm EDT			5-day change	1st Jan Change
0.02 ^USD	+33.33%		-28.57%	-83.81%

Mar. 15	Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	MT
Mar. 12	News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	DJ

Sorrento Therapeutics, Inc. Approves the Appointment of Elizabeth A. Czerepak as Director

November 18, 2021 at 06:04 am EST

On November 15, 2021, Sorrento Therapeutics, Inc. held its 2021 Annual Meeting of Stockholders. The shareholders approved the appointment of Elizabeth A. Czerepak as director.

Latest news about Sorrento Therapeutics, Inc.

Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	Mar. 15	MT
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	Mar. 12	DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET	Mar. 12	DJ
News Highlights : Top Company News of the Day - Tuesday at 1 AM ET	Mar. 12	DJ
Final DIP Financing Approved for Sorrento Therapeutics, Inc.	Mar. 12	CI
News Highlights : Top Company News of the Day - Monday at 11 PM ET	Mar. 11	DJ
News Highlights : Top Company News of the Day - Monday at 9 PM ET	Mar. 11	DJ
Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.	Mar. 11	CI
Motion for Asset Sale Approved for Sorrento Therapeutics, Inc.	Mar. 07	CI
Interim DIP Financing Approved for Sorrento Therapeutics, Inc.	Feb. 29	CI
Health Care Slips on Growth Doubts -- Health Care Roundup	Feb. 26	DJ
News Highlights : Top Company News of the Day - Friday at 7 PM ET	Feb. 23	DJ
News Highlights : Top Company News of the Day - Friday at 5 PM ET	Feb. 23	DJ
News Highlights : Top Financial Services News of the Day - Wednesday at 11 AM ET	Feb. 21	DJ
News Highlights : Top Financial Services News of the Day - Wednesday at 7 AM ET	Feb. 21	DJ
News Highlights : Top Financial Services News of the Day - Wednesday at 12 AM ET	Feb. 21	DJ
News Highlights : Top Financial Services News of the Day - Tuesday at 4 PM ET	Feb. 20	DJ
Motion for Case Dismissal Filed for Sorrento Therapeutics, Inc.	Feb. 08	CI
Sixth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	Feb. 04	CI
Fifth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	Dec. 17	CI
Second Modified Joint Liquidation Plan and DIscllosure Statement Approved for Sorrento Therapeutics, Inc.	Nov. 30	CI
Sorrento Therapeutics, Inc. Completes Reduction in U.S. Headcount from 123 to 90	Nov. 07	CI
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Chief Financial Officer	Nov. 07	CI
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Its Executive Vice President	Nov. 07	CI
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million.	Nov. 02	CI

Chart Sorrento Therapeutics, Inc.

Duration

Period

More charts

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Companyâs segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Companyâs immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
SORRENTO THERAPEUTICS, INC.	-83.81%	10.87M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.75%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-9.10%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs